Cian Healthcare Limited announced key governance decisions following its Board of Directors meeting held on March 16, 2026. The physical meeting, which commenced at 02:00 P.M. (IST) and concluded at 03:38 P.M. (IST), addressed critical authorization matters and leadership appointments in compliance with SEBI regulations.

Authorization of Key Managerial Personnel

The Board approved granting authorization to Key Managerial Personnel for determining the materiality of company events and information. This authorization enables designated personnel to make timely disclosures to BSE Limited under Regulation 30(5) of the SEBI Listing Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026.

This authorization framework ensures compliance with disclosure requirements while enabling efficient decision-making processes for material event reporting to stock exchanges.

New Chairperson Appointment

The Board designated Mr. Manish Goswami as the new Chairperson of the Board, effective March 16, 2026. Mr. Goswami, who serves as an Independent Non-Executive Director, will hold the Chairperson position for a tenure of 1 year. The appointment was made based on the recommendation of the company's Nomination and Remuneration Committee.

Regulatory Compliance

The decisions were made in compliance with Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company filed the disclosure with BSE Limited under scrip code 542678 and trading symbol CHCL, ensuring transparency with stakeholders and regulatory authorities.

The meeting outcome reflects Cian Healthcare Limited's commitment to maintaining robust governance structures while ensuring compliance with evolving regulatory requirements in the healthcare sector.

Cian Healthcare Limited has announced significant changes to its board composition following a board meeting held on March 16, 2026. The pharmaceutical company, which holds ISO 9001:2015 and WHO GMP certifications, has made two key directorial appointments that will strengthen its leadership structure.

Board Meeting Outcomes

The Board of Directors convened for meeting CHL/BM/2025-26/01 on March 16, 2026, from 02:00 P.M. to 03:38 P.M. (IST). Based on recommendations from the Nomination and Remuneration Committee, the board approved two significant appointments:

Managing Director Appointment

Mr. Rajesh Jain's designation has been changed from Non-Executive Director to Managing Director for a tenure of 3 consecutive years commencing from March 16, 2026. He brings over two decades of extensive professional experience across pharmaceuticals, retail, wholesale, manufacturing, laboratory services, and marketing sectors.

Educational Qualifications:

• Master of Pharmacy degree from Punjab Technical University (2013)
• Bachelor of Pharmacy degree from University of Rajasthan (1995)
• Currently pursuing PhD in pharmaceutical sciences

Mr. Jain is recognized as a dynamic professional with significant expertise in project management and production optimization within the pharmaceutical industry. His broad industry exposure has enabled him to develop strong leadership capabilities and deep understanding of competitive market environments.

Woman Director Appointment

Ms. Simmi Soni has been appointed as an Additional Director in the category of Woman Non-Executive Director. She brings over 15 years of extensive experience in administration, logistics management, and export coordination within the food supplement and pharmaceutical manufacturing sector.

Professional Experience:

• Since 2009: Pivotal role in strengthening administrative frameworks
• Expertise in logistics operations and export management processes
• Extensive experience in manufacturing support operations and regulatory coordination
• Successfully overseen coordination of material movement and finished product distribution across domestic and international markets

Ms. Soni is recognized for her ability to streamline operational procedures, enhance process efficiency, and facilitate effective cross-functional collaboration across departments while ensuring compliance with regulatory requirements.

Regulatory Compliance

Both appointments comply with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026. The company has confirmed that neither director is debarred from holding office by SEBI or any other applicable authority.

Next Steps

Both appointments are subject to approval by shareholders at the company's ensuing General Meeting. Ms. Soni will hold office as Additional Director until the date of the next General Meeting, while both directors will be liable to retire by rotation in accordance with the Companies Act, 2013 provisions.